p53 is a known negative regulator of the mevalonate pathway with increased cholesterol levels shown to promote tumorigenesis in a pre-clinical cancer models of breast carcinoma and hepatocellular carcinoma (HCC) (Freed-Pastor et al, 2012; Moon et al, 2019). Here, TP53 is linked to breast carcinoma.